Closed System Drug Transfer Device (CSTD) Market to grow 17.47% CAGR during the Forecast Period 2023-2032

Closed System Drug Transfer Device (CSTD) Market is estimated to register a CAGR of 17.47% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global Closed System Drug Transfer Device (CSTD) Market— Becton, Dickinson and Company (US), B. Braun SE (Germany), Epic Medical (Singapore), Simplivia Healthcare, Ltd. (Israel), JMS Co. Ltd (Japan), Equashield (US), ICU Medical, Inc (US), Yukon Medical (US), Caragen Ltd (Ireland), and Corvida Medical (US).

Market Highlights

The global closed system drug transfer device (CSTD) market is accounted for to register a CAGR of 17.47% during the forecast period and is estimated to reach USD 3.63 billion by 2032.

The increasing investment in healthcare infrastructure worldwide presents a substantial opportunity for the global Closed System Drug Transfer Device (CSTD) market. As governments and private investors allocate significant resources to bolster healthcare systems, the demand for advanced safety solutions like CSTDs is poised to rise. This investment fuels the expansion, modernization, and enhancement of healthcare facilities, creating a conducive environment for the widespread adoption of CSTDs.

Moreover, as healthcare infrastructure development fosters research, education, and preventive healthcare initiatives, it generates opportunities for CSTD manufacturers and providers to supply essential safety equipment and solutions that align with the evolving healthcare landscape. The collaborative efforts between the healthcare industry and infrastructure development create a synergy that not only advances patient care but also opens doors for businesses operating in the global healthcare market, facilitating innovation, economic growth, and improved healthcare access on a global scale.

The increasing use of hazardous drugs, oncology services, and home healthcare are increasing the demand for CSTDs, and stringent regulatory requirements within the healthcare industry are propelling market growth. However, high initial setup costs are expected to hamper the growth of the global market. Nevertheless, an increasing investment in healthcare infrastructure presents a substantial opportunity for the market is projected to create lucrative opportunities for market players.

Access full report @ https://www.marketresearchfuture.com/reports/closed-system-drug-transfer-device-market-7733

Segment Analysis

The global closed system drug transfer device (CSTD) market has been segmented based on type, closing mechanism, component, technology, and end user.

On the basis of the type, the market is segmented into barrier type and filtration type. The barrier type segment was attributed to holding the largest market share of over 83.6% in 2022 revenue as estimated by MRFR analysts. This is due to the growing geriatric population and rising awareness of CSTD devices.

Further, we estimate that the market segment would continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new product launches.

On the basis of the closing mechanism, the market is segmented into push to turn system, color-to-color alignment system, leur lock systems, and others. The push to turn system segment is projected to have the largest market share during the forecast period. This is due to increasing number of cancer incidences globally and the need for such devices to reduce the risk associated with handling hazardous drugs.

On the basis of the component, the market is segmented into vial access devices, syringe safety devices, bag/infusion set devices, and others. The diaphragm-based devices segment is projected to have the largest market share during the forecast period. This is due to growing awareness regarding usage and the increasing prevalence of cancer.

On the basis of the technology, the market is segmented into compartmentalized devices, diaphragm-based devices, and air filtration devices. The vial access devices segment is projected to have the largest market share during the forecast period. This is due to growing awareness about the availability of products and technological advancements.

On the basis of the end user the market is segmented into hospitals & clinics, specialty centers, and others. The hospitals & clinics segment is projected to have the largest market share during the forecast period. This is attributed to the high purchasing power of big hospitals and the growing healthcare infrastructure.

Regional Analysis

The global closed system drug transfer device (CSTD) Market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe closed system drug transfer device (CSTD) market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The closed system drug transfer device (CSTD) market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the world’s closed system drug transfer device (CSTD) market comprises of Middle East, Africa, and Latin America.

the country's increasing prevalence of cancer cases and the strong research and development infrastructure are expected to foster North America’s market growth. Moreover, the presence of major market players, high awareness about CSTD products among end users, and recent technological advancements are expected to support market growth.

Moreover, the Europe market has been persistently growing owing to increasing disposable income and the highly developed healthcare industry, prominent research, and development infrastructure, and accessibility of CSTD products across the region.

Additionally, market factors, such as the huge patient pool of cancer and government initiatives for healthcare reforms are driving the Asia-Pacific region’s growth.

Furthermore, the rest of the world's patient portal market is divided into the Middle East, Africa, and Latin America. The major factors driving the growth of the closed system drug transfer device (CSTD) market in the region are the increasing burden of cancer in Africa and rise in safety concerns of healthcare workers.

Key Findings of the Study

• The global closed system drug transfer device (CSTD) market is expected to reach USD 3.63 billion by 2032, at a CAGR of 17.47% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the availability of skilled workforce and low production cost in the region portrays in the Asia-Pacific region.


• Based on type, the barrier type segment was attributed to holding the largest market in 2022, with an approximate market share of around 83.6%.


• Becton, Dickinson and Company (US), B. BRAUN SE (Germany), Epic Medical (Singapore), Simplivia Healthcare, Ltd. (Israel), JMS Co. Ltd (Japan), Equashield (US), ICU Medical, Inc (US), Yukon Medical (US), Caragen Ltd (Ireland), and Corvida Medical (US) are the key market players.